BKI-1369

CAS : 1951431-22-3

Ref. 3D-BDD43122

Informations sur le produit

• Nom: BKI-1369
• CAS: 1951431-22-3

Description

BKI-1369 is an experimental drug in the class of benzimidazole derivatives that is being studied for use in the treatment of infectious diseases. It has been shown to have a broad spectrum of activity against bacteria and protozoa, including multidrug-resistant strains. BKI-1369 has been successful in animal studies with peroxides, which are toxic compounds generated by some bacteria. It has been shown to be active against c. parvum and intestinal-dwelling bacteria such as E. coli and Enterococcus faecalis. Clinical trials have demonstrated that BKI-1369 is effective in treating mucosal lesions caused by Chlamydia pneumoniae, Mycoplasma hominis, or C. parvum in humans or animals. This drug targets the enzyme thymidine phosphorylase, which is essential for bacterial growth and replication.

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 417.51 g/mol
• Formule: C₂₃H₂₇N₇O
• Degré de pureté: Min. 95%